Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E6 TCR T Cells for Vulvar HSIL
NCT03197025Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Jan 2018
- Primary completion
- May 2019
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of E6 T cell receptor in vulvar high-grade squamous intraepithelial lesion (2 arms), sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose at 30 days. Started Jan 2018; status: terminated.
02
Drugs
E6 T cell receptor
03
Conditions
vulvar high-grade squamous intraepithelial lesion
Beyond the preview
Go deeper on NCT03197025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03197025.